Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2021 2
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for epirubicin hcl mylan
Your search for epirubicine-hcl-mylan retrieved no results
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial.
Gluz O, Kuemmel S, Nitz U, Braun M, Lüdtke-Heckenkamp K, von Schumann R, Darsow M, Forstbauer H, Potenberg J, Uleer C, Grischke EM, Aktas B, Schumacher C, Zu Eulenburg C, Kates R, Jóźwiak K, Graeser M, Wuerstlein R, Baehner R, Christgen M, Kreipe HH, Harbeck N. Gluz O, et al. Ann Oncol. 2023 Jun;34(6):531-542. doi: 10.1016/j.annonc.2023.04.002. Epub 2023 Apr 14. Ann Oncol. 2023. PMID: 37062416 Clinical Trial.
PATIENTS AND METHODS: Within the WSG-ADAPT trial (NCT01779206), high-risk HR+/HER2- EBC patients were randomized to (neo)adjuvant 4 sb-paclitaxel 175 mg/m(2) q2w or 8 nab-paclitaxel 125 mg/m(2) q1w, followed by 4 epirubicin + cyclophosphamide (90 mg + 600 mg) q2w; inclusio …
PATIENTS AND METHODS: Within the WSG-ADAPT trial (NCT01779206), high-risk HR+/HER2- EBC patients were randomized to (neo)adjuvant 4 sb-pacli …
Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients.
Tzschaschel M, Friedl TWP, Schochter F, Schütze S, Polasik A, Fehm T, Pantel K, Schindlbeck C, Schneeweiss A, Schreier J, Tesch H, Lorenz R, Aivazova-Fuchs V, Häberle L, Fasching P, Janni W, Rack BK, Fink V. Tzschaschel M, et al. Clin Breast Cancer. 2023 Aug;23(6):e345-e353. doi: 10.1016/j.clbc.2023.05.011. Epub 2023 May 23. Clin Breast Cancer. 2023. PMID: 37336651 Clinical Trial.
MATERIALS AND METHODS: In the phase III SUCCESS A trial, 3754 patients with early BC were randomized to 3 cycles of fluorouracil, epirubicin and cyclophosphamide followed by 3 cycles of docetaxel with or without gemcitabine. ...
MATERIALS AND METHODS: In the phase III SUCCESS A trial, 3754 patients with early BC were randomized to 3 cycles of fluorouracil, epirubi …
Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302.
Ikeda M, Arai Y, Inaba Y, Tanaka T, Sugawara S, Kodama Y, Aramaki T, Anai H, Morita S, Tsukahara Y, Seki H, Sato M, Kamimura K, Azama K, Tsurusaki M, Sugihara E, Miyazaki M, Kobayashi T, Sone M. Ikeda M, et al. Liver Cancer. 2022 Jun 15;11(5):440-450. doi: 10.1159/000525500. eCollection 2022 Sep. Liver Cancer. 2022. PMID: 36158586 Free PMC article.
This randomized controlled trial was conducted to clarify whether selective TACE with drug-eluting beads (DEB-TACE) loaded with epirubicin or selective conventional TACE (cTACE) with epirubicin-ethiodized oil might be more effective for obtaining complete response(C …
This randomized controlled trial was conducted to clarify whether selective TACE with drug-eluting beads (DEB-TACE) loaded with epirubici …
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
Blohmer JU, Link T, Reinisch M, Just M, Untch M, Stötzer O, Fasching PA, Schneeweiss A, Wimberger P, Seiler S, Huober J, Thill M, Jackisch C, Rhiem K, Solbach C, Hanusch C, Seither F, Denkert C, Engels K, Nekljudova V, Loibl S; GBG and AGO-B. Blohmer JU, et al. JAMA Oncol. 2022 Jul 1;8(7):1010-1018. doi: 10.1001/jamaoncol.2022.1059. JAMA Oncol. 2022. PMID: 35588050 Free PMC article. Clinical Trial.
INTERVENTIONS: Patients were randomized to receive or not receive denosumab, 120 mg subcutaneously every 4 weeks for 6 cycles, and either nab-paclitaxel, 125 mg/m2 weekly for 12 weeks or days 1 and 8 every 3 weeks for 4 cycles (8 doses), followed by 4 cycles of epirubicin/ …
INTERVENTIONS: Patients were randomized to receive or not receive denosumab, 120 mg subcutaneously every 4 weeks for 6 cycles, and either na …
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.
Schneeweiss A, Michel LL, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, Kast K, Pohl-Rescigno E, Hanusch C, Link T, Untch M, Jackisch C, Blohmer JU, Fasching PA, Solbach C, Schmutzler RK, Huober J, Rhiem K, Nekljudova V, Lübbe K, Loibl S; GBG and AGO-B. Schneeweiss A, et al. Eur J Cancer. 2022 Jan;160:100-111. doi: 10.1016/j.ejca.2021.10.011. Epub 2021 Nov 17. Eur J Cancer. 2022. PMID: 34801353 Clinical Trial.
BACKGROUND: GeparOcto demonstrated that pathological complete response (pCR) of intense dose-dense epirubicin, paclitaxel and cyclophosphamide (iddEPC) was comparable to weekly paclitaxel/non-pegylated liposomal doxorubicin (plus carboplatin (PM(Cb) in triple-negative brea …
BACKGROUND: GeparOcto demonstrated that pathological complete response (pCR) of intense dose-dense epirubicin, paclitaxel and cycloph …
Qualitative and quantitative analysis of therapeutic solutions using Raman and infrared spectroscopy.
Makki AA, Bonnier F, Respaud R, Chtara F, Tfayli A, Tauber C, Bertrand D, Byrne HJ, Mohammed E, Chourpa I. Makki AA, et al. Spectrochim Acta A Mol Biomol Spectrosc. 2019 Jul 5;218:97-108. doi: 10.1016/j.saa.2019.03.056. Epub 2019 Mar 24. Spectrochim Acta A Mol Biomol Spectrosc. 2019. PMID: 30954803
In the present study, infrared (IR) and Raman spectroscopy have been employed for the analysis of 3 commercially available therapeutic solutions TEVA, MYLAN, CERUBIDINE, respectively containing doxorubicin, epirubicin and daunorubicin. ...
In the present study, infrared (IR) and Raman spectroscopy have been employed for the analysis of 3 commercially available therapeutic solut …
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).
Möbus V, Lück HJ, Ladda E, Klare P, Schmidt M, Schneeweiss A, Grischke EM, Wachsmann G, Forstbauer H, Untch M, Marmé F, Blohmer JU, Jackisch C, Huober J, Stickeler E, Reinisch M, Link T, Sinn BV, Janni W, Denkert C, Furlanetto J, Engels K, Solbach C, Schmatloch S, Rey J, Burchardi N, Loibl S; GBG and AGO-B. Möbus V, et al. Eur J Cancer. 2021 Oct;156:138-148. doi: 10.1016/j.ejca.2021.07.033. Epub 2021 Aug 24. Eur J Cancer. 2021. PMID: 34450552 Clinical Trial.
Two thousand eight hundred and eighty seven patients were randomised 1:1 between three courses each of idd epirubicin (E) 150 mg/m(2), nab-paclitaxel (nP) 330 mg/m(2) and cyclophosphamide (C) 2000 mg/m(2) (iddEnPC) versus four cycles of leucocyte nadir-based tailored and d …
Two thousand eight hundred and eighty seven patients were randomised 1:1 between three courses each of idd epirubicin (E) 150 mg/m(2) …